Baker Bros. Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Baker Bros. Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$1.5M	–	129
2017 Q2	$1.5M	Hold	50,000	–	–	0.01%	93
2017 Q1	$1.11M	Sell	50,000 -30,000	-38%	-$643K	0.01%	99
2016 Q4	$1.51M	Hold	80,000	–	–	0.01%	98
2016 Q3	$2.4M	Hold	80,000	–	–	0.02%	91
2016 Q2	$3.08M	Hold	80,000	–	–	0.03%	83
2016 Q1	$3.05M	Hold	80,000	–	–	0.03%	87
2015 Q4	$3.52M	Hold	80,000	–	–	0.03%	89
2015 Q3	$3.25M	Hold	80,000	–	–	0.03%	88
2015 Q2	$4.27M	Sell	80,000 -20,000	-20%	-$1.06M	0.04%	83
2015 Q1	$6.07M	Hold	100,000	–	–	0.05%	70
2014 Q4	$5.22M	Buy	+100,000	New	+$4.48M	0.05%	73

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Baker Bros. Advisors's JUNO Position: Q3 2017 in Review

Baker Bros. Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 50,000 shares — an estimated $1.5M sold.

Baker Bros. Advisors first reported a position in JUNO in Q4 2014 and held it in 11 quarters. The position peaked at $6.07M in Q1 2015. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

Baker Bros. Advisors reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Baker Bros. Advisors sold 50,000 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $1.5M.
Baker Bros. Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
Baker Bros. Advisors's Juno Therapeutics, Inc. position peaked at $6.07M in Q1 2015.
210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.